Paricalcitol - Revision history

Fire: Marked this version for translation

2024-04-12T14:14:04Z

Marked this version for translation

← Older revision		Revision as of 23:14, 12 April 2024
Line 1:		Line 1:
	<languages />		<languages />
	<translate>		<translate>
			<!--T:1-->
	{{short description\|Chemical compound}}		{{short description\|Chemical compound}}
	{{Drugbox		{{Drugbox
Line 60:		Line 61:
	}}		}}

			<!--T:2-->
	'''Paricalcitol''' (chemically it is '''19-nor-1,25-(OH)<sub>2</sub>-vitamin D<sub>2</sub>'''. Marketed by [[Abbott Laboratories]] under the trade name '''Zemplar''') is a [[pharmaceutical drug\|drug]] used for the prevention and treatment of [[secondary hyperparathyroidism]] (excessive secretion of [[parathyroid hormone]]) associated with [[chronic kidney failure]]. It is an [[analog (chemistry)\|analog]] of 1,25-dihydroxyergocalciferol, the active form of [[Vitamin D2\|vitamin D<sub>2</sub>]] (ergocalciferol).		'''Paricalcitol''' (chemically it is '''19-nor-1,25-(OH)<sub>2</sub>-vitamin D<sub>2</sub>'''. Marketed by [[Abbott Laboratories]] under the trade name '''Zemplar''') is a [[pharmaceutical drug\|drug]] used for the prevention and treatment of [[secondary hyperparathyroidism]] (excessive secretion of [[parathyroid hormone]]) associated with [[chronic kidney failure]]. It is an [[analog (chemistry)\|analog]] of 1,25-dihydroxyergocalciferol, the active form of [[Vitamin D2\|vitamin D<sub>2</sub>]] (ergocalciferol).

			<!--T:3-->
	<!-- Society and culture -->		<!-- Society and culture -->
	It was patented in 1989 and approved for medical use in 1998.		It was patented in 1989 and approved for medical use in 1998.

			<!--T:4-->
	==Medical uses==		==Medical uses==
	Its primary use in medicine is in the treatment of secondary [[hyperparathyroidism]] associated with [[chronic kidney disease]]. However current evidence is not sufficient to demonstrate an advantage of paricalcitol over non-selective vitamin D derivatives for this indication.		Its primary use in medicine is in the treatment of secondary [[hyperparathyroidism]] associated with [[chronic kidney disease]]. However current evidence is not sufficient to demonstrate an advantage of paricalcitol over non-selective vitamin D derivatives for this indication.

			<!--T:5-->
	==Adverse effects==		==Adverse effects==
	'''Adverse effects by frequency:'''<br />		'''Adverse effects by frequency:'''<br />
Line 73:		Line 78:
	* Nausea		* Nausea

			<!--T:6-->
	'''Common (1-10% frequency):'''		'''Common (1-10% frequency):'''
	{{div col\|colwidth=18em}}		{{div col\|colwidth=18em}}
Line 95:		Line 101:
	{{div col end}}		{{div col end}}

			<!--T:7-->
	'''Uncommon (0.1-1% frequency):'''		'''Uncommon (0.1-1% frequency):'''
	{{div col\|colwidth=18em}}		{{div col\|colwidth=18em}}
Line 176:		Line 183:
	{{div col end}}		{{div col end}}

			<!--T:8-->
	<sup>‡</sup> These are adverse effects only seen in patients with grade 3 or 4 chronic kidney disease.		<sup>‡</sup> These are adverse effects only seen in patients with grade 3 or 4 chronic kidney disease.
	<sup>†</sup> These are adverse effects only seen in patients with grade 5 chronic kidney disease.		<sup>†</sup> These are adverse effects only seen in patients with grade 5 chronic kidney disease.

			<!--T:9-->
	==Contraindications==		==Contraindications==
	Contraindications include:		Contraindications include:
Line 185:		Line 194:
	* Hypersensitivity to paricalcitol or any of its excipients		* Hypersensitivity to paricalcitol or any of its excipients

			<!--T:10-->
	whereas cautions include:		whereas cautions include:
	* Impaired liver function		* Impaired liver function
	* It is also advised that physicians regularly monitor their patients' [[calcium]] and [[phosphorus]] levels.		* It is also advised that physicians regularly monitor their patients' [[calcium]] and [[phosphorus]] levels.

			<!--T:11-->
	==Interactions==		==Interactions==
	Drugs that may interact with paricalcitol include:		Drugs that may interact with paricalcitol include:
Line 200:		Line 211:
	{{div col end}}		{{div col end}}

			<!--T:12-->
	==Overdose==		==Overdose==
	Electrolyte abnormalities (e.g. [[hypercalcaemia]] and [[hyperphosphataemia]]) are common overdose symptoms. Treatment is mostly supportive, with particular attention being paid to correcting electrolyte anomalies and reducing intake of calcium in both the form of supplementation and diet. As it is so heavily bound to plasma proteins [[haemodialysis]] is unlikely to be helpful in cases of overdose.		Electrolyte abnormalities (e.g. [[hypercalcaemia]] and [[hyperphosphataemia]]) are common overdose symptoms. Treatment is mostly supportive, with particular attention being paid to correcting electrolyte anomalies and reducing intake of calcium in both the form of supplementation and diet. As it is so heavily bound to plasma proteins [[haemodialysis]] is unlikely to be helpful in cases of overdose.

			<!--T:13-->
	Early symptoms of overdose can include:		Early symptoms of overdose can include:
	{{div col\|colwidth=18em}}		{{div col\|colwidth=18em}}
Line 218:		Line 231:
	It is worth noting, however, that may of these symptoms are also indicative of kidney failure and hence may be masked by the patient's condition.		It is worth noting, however, that may of these symptoms are also indicative of kidney failure and hence may be masked by the patient's condition.

			<!--T:14-->
	Late symptoms of overdose include:		Late symptoms of overdose include:
	{{div col\|colwidth=18em}}		{{div col\|colwidth=18em}}
Line 240:		Line 254:
	{{div col end}}		{{div col end}}

			<!--T:15-->
	==Mechanism of action==		==Mechanism of action==
	[[File:Paricalcitol structure.svg\|thumb\|left\|3D structure of paricalcitol]]{{clear left}}		[[File:Paricalcitol structure.svg\|thumb\|left\|3D structure of paricalcitol]]{{clear left}}
	Like 1,25-dihydroxyergocalciferol, paricalcitol acts as an [[agonist]] at the [[vitamin D receptor]] and thereby lowers [[parathyroid hormone]] levels in the blood.		Like 1,25-dihydroxyergocalciferol, paricalcitol acts as an [[agonist]] at the [[vitamin D receptor]] and thereby lowers [[parathyroid hormone]] levels in the blood.

			<!--T:16-->
	==Pharmacokinetics==		==Pharmacokinetics==
	The plasma concentration of paricalcitol decreases rapidly and log-linearly within two hours after initial intravenous administration. Therefore, it is not expected to accumulate with multiple dosing, since paricalcitol is usually given no more frequently than every other day (3 times per week).		The plasma concentration of paricalcitol decreases rapidly and log-linearly within two hours after initial intravenous administration. Therefore, it is not expected to accumulate with multiple dosing, since paricalcitol is usually given no more frequently than every other day (3 times per week).

			<!--T:17-->
	{{Vitamins}}		{{Vitamins}}
	{{Calcium homeostasis}}		{{Calcium homeostasis}}
	{{Vitamin D receptor modulators}}		{{Vitamin D receptor modulators}}

			<!--T:18-->
	{{二次利用\|date=20 December 2023}}		{{二次利用\|date=20 December 2023}}
	[[Category:Secosteroids]]		[[Category:Secosteroids]]

Fire at 14:13, 12 April 2024

2024-04-12T14:13:31Z

← Older revision		Revision as of 23:13, 12 April 2024
Line 1:		Line 1:
			<languages />
			<translate>
	{{short description\|Chemical compound}}		{{short description\|Chemical compound}}
	{{Drugbox		{{Drugbox
Line 253:		Line 255:
	[[Category:Vitamin D]]		[[Category:Vitamin D]]
	[[Category:Drugs developed by AbbVie]]		[[Category:Drugs developed by AbbVie]]
			</translate>

Fire at 14:08, 12 April 2024

2024-04-12T14:08:47Z

← Older revision		Revision as of 23:08, 12 April 2024
Line 23:		Line 23:
	\| routes_of_administration = Oral, Intravenous		\| routes_of_administration = Oral, Intravenous
	<!--Pharmacokinetic data-->		<!--Pharmacokinetic data-->
	\| bioavailability = 72%~~<ref name = MSR/>~~		\| bioavailability = 72%
	\| protein_bound = 99.8%~~<ref name = MSR/>~~		\| protein_bound = 99.8%
	\| metabolism = [[Hepatic]]~~<ref name = MSR/>~~		\| metabolism = [[Hepatic]]
	\| elimination_half-life = 14-20 hours~~<ref name = MSR/>~~		\| elimination_half-life = 14-20 hours
	\| excretion = Faeces (74%), urine (16%)~~<ref name = MSR/>~~		\| excretion = Faeces (74%), urine (16%)
	<!--Identifiers-->		<!--Identifiers-->
	\| CAS_number_Ref = {{cascite\|correct\|??}}		\| CAS_number_Ref = {{cascite\|correct\|??}}
Line 199:		Line 199:

	==Overdose==		==Overdose==
	Electrolyte abnormalities (e.g. [[hypercalcaemia]] and [[hyperphosphataemia]]) are common overdose symptoms. Treatment is mostly supportive, with particular attention being paid to correcting electrolyte anomalies and reducing intake of calcium in both the form of supplementation and diet.~~<ref name = EMC/>~~ As it is so heavily bound to plasma proteins [[haemodialysis]] is unlikely to be helpful in cases of overdose.		Electrolyte abnormalities (e.g. [[hypercalcaemia]] and [[hyperphosphataemia]]) are common overdose symptoms. Treatment is mostly supportive, with particular attention being paid to correcting electrolyte anomalies and reducing intake of calcium in both the form of supplementation and diet. As it is so heavily bound to plasma proteins [[haemodialysis]] is unlikely to be helpful in cases of overdose.

	Early symptoms of overdose can include:		Early symptoms of overdose can include:

Fire: Created page with "{{short description|Chemical compound}} {{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 445909355 | IUPAC_name = (1''R'',3''R'',7''E'',17β)-17-[(1''R'',2''E'',4''S'')-5-hydroxy-1,4,5-trimethylhex-2-en-1-yl]-9,10-secoestra-5,7-diene-1,3-diol | image = Paricalcitol.svg | width = 200px | image2 = Paricalcitol3Dan.gif | width2 = 200px | tradename = Zemplar | Drugs.com = {{drugs.com|monograph|paricalcitol}} | MedlinePlus..."

2024-04-12T14:08:08Z

Created page with "{{short description|Chemical compound}} {{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 445909355 | IUPAC_name = (1''R'',3''R'',7''E'',17β)-17-[(1''R'',2''E'',4''S'')-5-hydroxy-1,4,5-trimethylhex-2-en-1-yl]-9,10-secoestra-5,7-diene-1,3-diol | image = Paricalcitol.svg | width = 200px | image2 = Paricalcitol3Dan.gif | width2 = 200px  | tradename = Zemplar | Drugs.com = {{drugs.com|monograph|paricalcitol}} | MedlinePlus..."

New page

{{short description|Chemical compound}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 445909355
| IUPAC_name = (1''R'',3''R'',7''E'',17β)-17-[(1''R'',2''E'',4''S'')-5-hydroxy-1,4,5-trimethylhex-2-en-1-yl]-9,10-secoestra-5,7-diene-1,3-diol
| image = Paricalcitol.svg
| width = 200px
| image2 = Paricalcitol3Dan.gif
| width2 = 200px

| tradename = Zemplar
| Drugs.com = {{drugs.com|monograph|paricalcitol}}
| MedlinePlus = a682335
| pregnancy_AU = C
| pregnancy_US = C
| pregnancy_category =
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| legal_status =
| routes_of_administration = Oral, Intravenous

| bioavailability = 72%<ref name = MSR/>
| protein_bound = 99.8%<ref name = MSR/>
| metabolism = [[Hepatic]]<ref name = MSR/>
| elimination_half-life = 14-20 hours<ref name = MSR/>
| excretion = Faeces (74%), urine (16%)<ref name = MSR/>

| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 131918-61-1
| ATC_prefix = H05
| ATC_suffix = BX02
| ATC_supplemental =
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 7931
| PubChem = 5281104
| IUPHAR_ligand = 2791
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00910
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4444552
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6702D36OG5
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00930
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1200622

| chemical_formula =
| C=27 | H=44 | O=3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BPKAHTKRCLCHEA-UBFJEZKGSA-N
| synonyms = (1''R'',3''S'')-5-[2-[(1''R'',3a''R'',7a''S'')-1-<nowiki>[</nowiki>(2''R'',5''S'')-6-hydroxy-5,6-dimethyl-3''E''-hepten-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1''H''-inden-4-ylidene]ethylidene]-cyclohexane-1,3-diol
}}

'''Paricalcitol''' (chemically it is '''19-nor-1,25-(OH)2-vitamin D2'''. Marketed by [[Abbott Laboratories]] under the trade name '''Zemplar''') is a [[pharmaceutical drug|drug]] used for the prevention and treatment of [[secondary hyperparathyroidism]] (excessive secretion of [[parathyroid hormone]]) associated with [[chronic kidney failure]]. It is an [[analog (chemistry)|analog]] of 1,25-dihydroxyergocalciferol, the active form of [[Vitamin D2|vitamin D2]] (ergocalciferol).


It was patented in 1989 and approved for medical use in 1998.

==Medical uses==
Its primary use in medicine is in the treatment of secondary [[hyperparathyroidism]] associated with [[chronic kidney disease]]. However current evidence is not sufficient to demonstrate an advantage of paricalcitol over non-selective vitamin D derivatives for this indication.

==Adverse effects==
'''Adverse effects by frequency:''' 
'''Very common (>10% frequency):'''
* Nausea

'''Common (1-10% frequency):'''
{{div col|colwidth=18em}}
* Diarrhoea†
* [[Oedema]]
* Allergic reaction
* [[Arthritis]]
* Dizziness†
* Stomach discomfort‡
* [[Gastroesophageal reflux disease]]†
* [[Acne]]†
* [[Hypercalcaemia]]†
* [[Hypocalcaemia]]†
* [[Hyperphosphataemia]]
* Decreased appetite†
* Headache
* Breast tenderness†
* Taste changes
* [[Hypoparathyroidism]]
* Vertigo
* Rash‡
{{div col end}}

'''Uncommon (0.1-1% frequency):'''
{{div col|colwidth=18em}}
* Abnormal hepatic enzymes‡
* Constipation‡
* Dry mouth‡
* [[Pruritus|Itchiness]]‡
* [[Urticaria|Hives]]
* Hypersensitivity‡
* Muscle spasms‡
* Bleeding time prolonged
* Aspartate aminotransferase increased
* Laboratory test abnormal
* Weight loss
* Elevated blood creatinine
* Cardiac arrest
* Arrhythmia
* Atrial flutter
* [[Anaemia]]
* [[Leucopenia]]
* Lymphadenopathy
* Coma
* [[Cerebrovascular accident|Stroke]]
* [[Transient ischemic attack]]
* [[Vasovagal syncope|Fainting]]
* [[Myoclonus]]
* [[Hypoaesthesia]]
* [[Paraesthesia]]
* [[Glaucoma]]
* [[Conjunctivitis]]
* Ear disorder
* Pulmonary oedema
* Asthma
* [[Dyspnoea|Shortness of breath]]
* [[Epistaxis|Nose bleed]]
* Cough
* Rectal haemhorrhage
* [[Colitis]]
* [[Gastritis]]
* [[Dyspepsia|Indigestion]]
* [[Dysphagia|Difficulty swallowing]]
* Gastrointestinal disorder
* Gastrointestinal haemorrhage
* Bullous dermatitis
* [[Alopecia|Hair loss]]
* [[Hirsutism]]
* [[Hyperhidrosis]]
* [[Arthralgia|Joint pain]]
* Joint stiffness
* Back pain
* Muscle twitching
* [[Myalgia|Muscle aches]]
* [[Hyperparathyroidism]]
* [[Hyperkalaemia]]
* [[Hypocalcemia]]
* [[Breast cancer]]
* [[Sepsis]]
* [[Pneumonia]]
* Infection
* [[Pharyngitis]]
* Vaginal infection
* Influenza
* [[Hypertension|High blood pressure]]
* [[Hypotension]]
* Gait disturbance
* Injection site pain
* [[Pyrexia|Fever]]
* Chest pain
* Condition aggravated
* [[Asthenia|Muscle weakness]]
* [[Malaise]]
* Thirst
* Breast pain
* [[Erectile dysfunction|Impotence]]
* Confusional state
* Delirium
* Depersonalization
* Agitation
* Insomnia
* Nervousness
{{div col end}}

‡ These are adverse effects only seen in patients with grade 3 or 4 chronic kidney disease.
† These are adverse effects only seen in patients with grade 5 chronic kidney disease.

==Contraindications==
Contraindications include:
* [[Hypervitaminosis D|Vitamin D intoxication]]
* [[Hypercalcaemia]]
* Hypersensitivity to paricalcitol or any of its excipients

whereas cautions include:
* Impaired liver function
* It is also advised that physicians regularly monitor their patients' [[calcium]] and [[phosphorus]] levels.

==Interactions==
Drugs that may interact with paricalcitol include:
{{div col|colwidth=30em}}
* [[Ketoconazole]], as it may interfere with paricalcitol's metabolism in the liver.
* [[Digitoxin]], hypercalcaemia due to any cause can exacerbate the toxicity of digitoxin.
* [[Thiazide]] diuretics or calcium supplements as [[hypercalcaemia]] may be induced by this combination
* [[Magnesium]]-containing products such as [[antacids]] may increase the risk of [[hypermagnesemia]].
* [[Aluminium]]-containing products such as antacids may increase the risk of [[aluminium toxicity]].
* Drugs that interfere with the absorption of fat-soluble vitamins, such as [[cholestyramine]] may interfere with the absorption of paricalcitol.
{{div col end}}

==Overdose==
Electrolyte abnormalities (e.g. [[hypercalcaemia]] and [[hyperphosphataemia]]) are common overdose symptoms. Treatment is mostly supportive, with particular attention being paid to correcting electrolyte anomalies and reducing intake of calcium in both the form of supplementation and diet.<ref name = EMC/> As it is so heavily bound to plasma proteins [[haemodialysis]] is unlikely to be helpful in cases of overdose.

Early symptoms of overdose can include:
{{div col|colwidth=18em}}
* Weakness
* Headache
* Somnolence
* Nausea
* Vomiting
* Dry mouth
* Constipation
* Muscle pain
* Bone pain
* Metallic taste in the mouth.
{{div col end}}
It is worth noting, however, that may of these symptoms are also indicative of kidney failure and hence may be masked by the patient's condition.

Late symptoms of overdose include:
{{div col|colwidth=18em}}
* [[Anorexia (symptom)|Loss of appetite]]
* Weight loss
* [[Conjunctivitis]] (calcific)
* [[Pancreatitis]]
* Photophobia
* Rhinorrhoea
* Pruritus
* Hyperthermia
* Decreased libido
* Elevated BUN
* Hypercholesterolaemia
* Elevated AST and ALT
* Ectopic calcification
* Hypertension
* Cardiac arrhythmias
* Somnolence
* Death
* Psychosis (rare)
{{div col end}}

==Mechanism of action==
[[File:Paricalcitol structure.svg|thumb|left|3D structure of paricalcitol]]{{clear left}}
Like 1,25-dihydroxyergocalciferol, paricalcitol acts as an [[agonist]] at the [[vitamin D receptor]] and thereby lowers [[parathyroid hormone]] levels in the blood.

==Pharmacokinetics==
The plasma concentration of paricalcitol decreases rapidly and log-linearly within two hours after initial intravenous administration. Therefore, it is not expected to accumulate with multiple dosing, since paricalcitol is usually given no more frequently than every other day (3 times per week).

{{Vitamins}}
{{Calcium homeostasis}}
{{Vitamin D receptor modulators}}

{{二次利用|date=20 December 2023}}
[[Category:Secosteroids]]
[[Category:Vitamin D]]
[[Category:Drugs developed by AbbVie]]